After NACT, mostly with cisplatin, there was a significant decrease in Ki67 and PD-L1 expression specifically on tumor cells, whereas a significant increase in CD4+, CD8+, CD20+, CD56+, and PD-1+ cells was observed in >50% of the patients. Here, CD8A is linked to neoplasm.